Anti-infective drug shortages pose significant problems for clinicians and are a rapidly evolving public-health emergency that may require government oversight, according to an article published online January 19 in Clinical Infectious Diseases.
Anti-infective drug shortages pose significant problems for clinicians and are a rapidly evolving public-health emergency that may require government oversight, according to an article published online January 19 in Clinical Infectious Diseases.
The number of infectious disease drug shortages rose from 6 in 2005 to 17 in 2010, reports Milena M. Griffith, PharmD, lead author, and colleagues. Anti-infective drugs represented 13% of the 193 currently unavailable medications as of February 2011. The impact of these shortages is probably realized in delays to effective therapy, suboptimal therapeutic selections, and incorrect substitutions.
Anti-infective drugs frequently represent irreplaceable life-saving treatments, particularly for hospitalized patients because there are some drugs for which it is hard to find an alternative. Anti-infective shortages are becoming more crucial in infectious diseases because more organisms are developing resistance to commonly prescribed drugs. This comes at a time when the number of new anti-infective drugs is declining.
Although 4 new molecular anti-infective entities became available in 2005, 2006, and 2007, that number dropped to 1 in 2008, with 2 in 2009, and 1 in 2010, the researchers report.
Enhanced oversight by governmental agencies may be necessary to identify and correct shortages of these life-saving anti-infectives. Bills such as the Preserving Access to Life-Saving Medications Act could provide FDA with the appropriate authority to minimize the impact of drug shortages.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
2 Commerce Drive
Cranbury, NJ 08512